Seagen, Genmab Present Tisotumab Vedotin Combo Data In Cervical Cancer

  • Seagen Inc SGEN and Genmab A/S GMAB have interim data from two Phase 1b/2 innovaTV 205 trial cohorts. The trial is evaluating its antibody-drug conjugate tisotumab vedotin (TV) in recurrent or metastatic cervical cancer.
  • New data showed some strong results in combination with the chemotherapy carboplatin or Merck & Co Inc's MRK Keytruda across multiple lines of therapy for recurrent or metastatic patients.
  • The data were presented at the European Society for Medical Oncology (ESMO21).
  • According to cohort data, the TV-carbo combo posted a response rate of 55%, including four complete responses and 14 partial responses, in first-line recurrent or metastatic cervical cancer patients.
  • At a median follow-up of 7.9 months, the combo's duration was 8.3 months, with a median progression-free survival (PFS) of 9.5 months.
  • Meanwhile, a combination of TV and Keytruda in second- or third-line cervical cancer patients posted a 38% response rate out of 34 patients, with two complete responses and 11 partial responses reported. 
  • The median time to response was 1.4 months, with a median follow-up of 13.0 months and a median duration of response of 13.8 months. Median PFS was 5.6 months.
  • Price Action: GMAB shares closed 1.99% higher at $43.12, and SGEN stock closed 1.72% higher at $156.21 on Friday.
  • Check out our coverage of the European Society for Medical Oncology Congress (ESMO21).
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralBriefsCervical CancerESMO21Phase 1 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!